mutLBSgeneDB |
Gene summary for TDRD3 |
Gene summary |
Basic gene Info. | Gene symbol | TDRD3 |
Gene name | tudor domain containing 3 | |
Synonyms | - | |
Cytomap | UCSC genome browser: 13q21.2 | |
Type of gene | protein-coding | |
RefGenes | NM_001146070.1, NM_001146071.1,NM_030794.2, | |
Description | tudor domain-containing protein 3 | |
Modification date | 20141207 | |
dbXrefs | MIM : 614392 | |
HGNC : HGNC | ||
Ensembl : ENSG00000083544 | ||
HPRD : 11625 | ||
Vega : OTTHUMG00000017007 | ||
Protein | UniProt: Q9H7E2 go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_TDRD3 | |
BioGPS: 81550 | ||
Pathway | NCI Pathway Interaction Database: TDRD3 | |
KEGG: TDRD3 | ||
REACTOME: TDRD3 | ||
Pathway Commons: TDRD3 | ||
Context | iHOP: TDRD3 | |
ligand binding site mutation search in PubMed: TDRD3 | ||
UCL Cancer Institute: TDRD3 | ||
Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO Term | PubMed ID | GO:1903506 | regulation of nucleic acid-templated transcription | 21172665 |
Top |
Ligand binding site mutations for TDRD3 |
Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.) : non-synonymous mutation on LBS, Circle size denotes number of samples. |
Cancer type specific mutLBS sorted by frequency |
LBS | AAchange of nsSNV | Cancer type | # samples | Y573 | R574Q | COAD | 1 | Y594,N596 | G595R | UCEC | 1 |
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
Top |
Protein structure related information for TDRD3 |
Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
: nsSNV at non-LBS: nsSNV at LBS |
nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
LBS | AAchange of nsSNV | Relative stability change | Y573 | R574Q | -1.0295507 | Y594 | G595R | -0.49256225 | N596 | G595R | -0.49256225 |
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
Structure image for TDRD3 from PDB |
Top |
Differential gene expression and gene-gene network for TDRD3 |
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
Top |
Top |
Phenotype information for TDRD3 |
Gene level disease information (DisGeNet) |
Disease ID | Disease name | # PubMed | Association type |
Mutation level pathogenic information (ClinVar annotation) |
Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
Top |
Pharmacological information for TDRD3 |
Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
Drug information targeting mutLBSgene (Approved drugs only) |
Drug status | DrugBank ID | Name | Type | Drug structure |
Gene-centered ligand-gene interaction network |
Ligands binding to mutated ligand binding site of TDRD3 go to BioLip |
Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | III | Peptide ligand (TYR,SER,PRO,SER,SER,PRO,DA2,TYR,THR,PRO,GLN,SER,PRO) | 2lto | A | Y573 Y594 N596 |
Top |
Conservation information for LBS of TDRD3 |
Multiple alignments for Q9H7E2 in multiple species |
LBS | AA sequence | # species | Species | E568 | FALYWEDNKFY | 4 | Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus | E568 | LALYWEDNKFY | 2 | Danio rerio, Bos taurus | E568 | LALYWEDNKYY | 1 | Xenopus tropicalis | E598 | DYGNYEEVLLS | 5 | Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus, Bos taurus | E598 | DYGNCEEVLLD | 1 | Danio rerio | E598 | DYGNYEEVLLE | 1 | Xenopus tropicalis | F591 | TAVVKFIDYGN | 2 | Homo sapiens, Bos taurus | F591 | TAVVKFSDYGN | 2 | Xenopus tropicalis, Gallus gallus | F591 | TAVVKFTDYGN | 2 | Mus musculus, Rattus norvegicus | F591 | TAVVVFSDYGN | 1 | Danio rerio | N596 | FIDYGNYEEVL | 2 | Homo sapiens, Bos taurus | N596 | FSDYGNYEEVL | 2 | Xenopus tropicalis, Gallus gallus | N596 | FTDYGNYEEVL | 2 | Mus musculus, Rattus norvegicus | N596 | FSDYGNCEEVL | 1 | Danio rerio | W567 | CFALYWEDNKF | 4 | Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus | W567 | CLALYWEDNKF | 2 | Danio rerio, Bos taurus | W567 | CLALYWEDNKY | 1 | Xenopus tropicalis | Y566 | ECFALYWEDNK | 4 | Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus | Y566 | ECLALYWEDNK | 2 | Xenopus tropicalis, Bos taurus | Y566 | QCLALYWEDNK | 1 | Danio rerio | Y573 | EDNKFYRAEVE | 5 | Homo sapiens, Gallus gallus, Mus musculus, Rattus norvegicus, Bos taurus | Y573 | EDNKFYRARID | 1 | Danio rerio | Y573 | EDNKYYRAEVE | 1 | Xenopus tropicalis | Y594 | VKFIDYGNYEE | 2 | Homo sapiens, Bos taurus | Y594 | VKFSDYGNYEE | 2 | Xenopus tropicalis, Gallus gallus | Y594 | VKFTDYGNYEE | 2 | Mus musculus, Rattus norvegicus | Y594 | VVFSDYGNCEE | 1 | Danio rerio |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |